Credit Suisse’s UroGen Pharma URGN Stock Holding History

Credit Suisse’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	$18M	Hold	1,200,000	–	–	0.02%	663
2023 Q4	$18M	Buy	1,200,000 +140,000	+13%	+$1.82M	0.02%	694
2023 Q3	$14.9M	Hold	1,060,000	–	–	0.02%	737
2023 Q2	$11M	Hold	1,060,000	–	–	0.01%	881
2023 Q1	$9.79M	Hold	1,060,000	–	–	0.01%	950
2022 Q4	$9.4M	Hold	1,060,000	–	–	0.01%	965
2022 Q3	$8.82M	Sell	1,060,000 -10	-0%	-$83	0.01%	977
2022 Q2	$8.68M	Sell	1,060,010 -25,511	-2%	-$175K	0.01%	993
2022 Q1	$9.46M	Sell	1,085,521 -228	-0%	-$1.78K	0.01%	1072
2021 Q4	$10.3M	Buy	1,085,749 +78	+0%	+$1.1K	0.01%	1485
2021 Q3	$18.3M	Sell	1,085,671 -197	-0%	-$3.12K	0.01%	1126
2021 Q2	$16.6M	Sell	1,085,868 -34,843	-3%	-$630K	0.01%	1247
2021 Q1	$21.8M	Sell	1,120,711 -360	-0%	-$7.64K	0.01%	1112
2020 Q4	$20.2M	Buy	1,121,071 +6,788	+0.6%	+$142K	0.01%	1158
2020 Q3	$21.5M	Buy	1,114,283 +201,105	+22%	+$4.55M	0.01%	989
2020 Q2	$23.9M	Buy	913,178 +244,175	+36%	+$5.97M	0.02%	860
2020 Q1	$11.9M	Sell	669,003 -432	-0.1%	-$11.7K	0.01%	1093
2019 Q4	$22.3M	Buy	669,435 +29,974	+5%	+$818K	0.02%	960
2019 Q3	$15.2M	Buy	639,461 +66,899	+12%	+$2.19M	0.01%	1080
2019 Q2	$20.6M	Buy	572,562 +56,953	+11%	+$2.1M	0.02%	912
2019 Q1	$19M	Buy	515,609 +79,033	+18%	+$3.31M	0.02%	893
2018 Q4	$18.8M	Buy	436,576 +16,748	+4%	+$753K	0.02%	822
2018 Q3	$19.8M	Buy	419,828 +145,627	+53%	+$6.77M	0.02%	882
2018 Q2	$13.6M	Sell	274,201 -77,799	-22%	-$4.53M	0.01%	1061
2018 Q1	$17.5M	Buy	352,000 +128,000	+57%	+$6.41M	0.02%	932
2017 Q4	$8.34M	Buy	224,000 +124,000	+124%	+$4.42M	0.01%	1411
2017 Q3	$3.15M	Buy	+100,000	New	+$2.21M	﹤0.01%	2160

Other funds holding URGN

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

JFG

Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

Credit Suisse's URGN Position: Q1 2024 in Review

Credit Suisse held its UroGen Pharma (URGN) position steady in Q1 2024 at 1,200,000 shares worth $18M. The position accounts for 0.02% of the portfolio, ranked #663.

Credit Suisse first reported a position in URGN in Q3 2017 and has held it in 27 quarters since. The position peaked at $23.9M in Q2 2020. 112 funds tracked by Wall St. Rank hold URGN as of Q1 2024.

Credit Suisse held 1,200,000 shares of UroGen Pharma worth $18M as of Q1 2024.
Credit Suisse left its UroGen Pharma share count unchanged in Q1 2024.
UroGen Pharma made up 0.02% of Credit Suisse's portfolio in Q1 2024, its #663 holding.
Credit Suisse first reported a position in UroGen Pharma in Q3 2017 and has held it in 27 quarters since.
Credit Suisse's UroGen Pharma position peaked at $23.9M in Q2 2020.
112 funds tracked by Wall St. Rank held UroGen Pharma as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.